Mabpharm Limited reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 28.85 million compared to CNY 81.25 million a year ago. Net loss was CNY 116.81 million compared to CNY 145.16 million a year ago.

Basic loss per share from continuing operations was CNY 0.03 compared to CNY 0.04 a year ago. Diluted loss per share from continuing operations was CNY 0.03 compared to CNY 0.04 a year ago.